CD274 and neoplasm: Based on the evidence that anti-angiogenic agents such as bevacizumab may modulate the tumor immune microenvironment and decrease the expression of regulatory checkpoints on tumor-infiltrating lymphocytes (79), a single-arm, open-label, nonrandomized study has recently evaluated the association of bevacizumab with the anti-PD-L1 Ab atezolizumab in patients with advanced, progressive, well-differentiated NETs (71).